Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Daiichi Sankyo
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
During the Phase 1 and Phase 2 portions of the study, participant eligibility criteria are identical except for prior treatment for anaplastic thyroid cancer (ATC). During Phase 1, eligible participants may have received prior chemotherapy while during Phase 2, eligible participants must be chemotherapy naïve.
Histologically or cytologically diagnosed, advanced ATC
Measurable lesion(s)
Lesion(s) (primary or metastatic) with viable tumor tissue accessible for repeated biopsy
Age equal to or older than 18 years
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
Adequate organ and bone marrow function
Agreement to use effective contraception while on treatment and for equal to or greater than 3 months after end of treatment
Pregnant or breastfeeding
You may not be if
Medical history of diabetes mellitus requiring treatment with insulin or oral agents; no pleural or pericardial effusion or clinically significant pulmonary or cardiovascular disease.
Clinically active brain metastasis, uncontrolled seizure disorder, spinal cord compression, or carcinomatous meningitis
Clinically significant active infection requiring antibiotic or antiretroviral therapy
Concomitant use of other thiazolidinediones (TZDs)
Clareo Health | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
